Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 317

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 317
---
 Property and equipment are carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets (generally fiveto seven years). Leasehold improvements are amortized straight-line over the shorter of the lease term or the estimated useful life of the asset. Property and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. Noimpairment was recorded for the years ended December 31, 2024 and 2023. Lease Accounting- The Company recognizes right-of-uselease assets and corresponding liabilities arising from leasing activities over the requisite lease period. I ncome Taxes- Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. In December 2023, the FASB issued ASU No. 2023-09,Income Taxes ( Topic 740), which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU 2023-09,public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU 2023-09are effective fiscal years beginning after December 31, 2024, and early adoption is permitted. The Company does not believe that the adoption of ASU 2023-09will have a material impact on its consolidated financial statements. Grant Income- In April 2021, the Company received approval from the Department of Health and Human Services for a $ 400,000grant. The grant was to conduct research for a low-costtopical immunotherapy formulation suitable for treating cervical cancer in low and middle-income countries and low resource settings in the U.S. Additionally, the Company assumed in the reverse merger a $ 2,000,000Business Innovation Research grant, a two year grant that was initiated in June 2023 and set to expire in June 2025, to support the clinical development of REM-001for the treatment of CMBC and had a remaining balance of $ 900,000as of the merger date. For the years ended December 31, 2024 and 2023, the Company recognized $ 58,000and $ 42,000